



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Poster: ABCL-360

**Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)**

Carmelo Carlo-Stella<sup>1\*</sup>, Cyrus Khan<sup>2</sup>, Martin Hutchings<sup>3</sup>, Fritz C. Offner<sup>4</sup>, Franck Morschhauser<sup>5</sup>, Emmanuel Bachy<sup>6</sup>, Michael Crump<sup>7</sup>, Anna Sureda<sup>8</sup>, Gloria Iacoboni<sup>9</sup>, Corinne Haioun<sup>10</sup>, David Perez-Callejo<sup>11</sup>, Linda Lundberg<sup>11</sup>, James Relf<sup>12</sup>, Emma Clark<sup>12</sup>, David Carlile<sup>12</sup>, Emily Piccione<sup>13</sup>, Anton Belousov<sup>11</sup>, Kathryn Humphrey<sup>12</sup>, Michael J. Dickinson<sup>14</sup>

<sup>1</sup>Humanitas University and Humanitas Research Hospital, Milan, Italy, <sup>2</sup>Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA, <sup>3</sup>Rigshospitalet, Copenhagen, Denmark, <sup>4</sup>Universitair Ziekenhuis Gent, Ghent, Belgium, <sup>5</sup>Hôpital Claude Huriez and Centre Hospitalier Régional Universitaire de Lille, Lille, France, <sup>6</sup>Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France, <sup>7</sup>Princess Margaret Hospital, Toronto, ON, Canada, <sup>8</sup>Institut Català d'Oncologia Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain, <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>10</sup>Hopital Henri Mondor, AP-HP, Créteil, France, <sup>11</sup>F Hoffmann-La Roche Ltd, Basel, Switzerland, <sup>12</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>13</sup>Genentech, Inc., South San Francisco, CA, USA, <sup>14</sup>Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia

Poster: ABCL-230

**Prevalence, Patterns, and Predictors of Venous Thromboembolic Events in Patients Undergoing Salvage Chemotherapy and Autologous Stem Cell Transplant for Relapsed Lymphomas**

Mohammad Ma'kosh<sup>1,2</sup>, Rawan Mustafa<sup>1\*</sup>, Mohammad Alrwashdeh<sup>1</sup>, Nayef Abdel-Razeq<sup>1</sup>, Rozan Alfar<sup>1</sup>, Sarah Edaily<sup>1</sup>, Rayan Bater<sup>1</sup>, Mais Zmaily<sup>3</sup>, Mohammad Almomani<sup>1</sup>, Hikmat Abdel-Razeq<sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan, <sup>2</sup>School of Medicine, University of Jordan, Amman-Jordan, <sup>3</sup>Department of Radiology, King Hussein Cancer Center, Amman, Jordan

Poster: ABCL-238

**Determinants of Quality of Life in Non-Hodgkin Lymphoma Patients: Moldavian Experiences**

Buruiana Sanda<sup>1\*</sup>, Maria Robu<sup>1</sup>, Victor Tomacinschi<sup>1,2</sup>, Aliona Golub<sup>2</sup>, Cristina Catan<sup>2</sup>, Aliona Monu<sup>2</sup>

<sup>1</sup>Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, <sup>2</sup>Hematology Department of Oncological Institute, Chisinau, Republic of Moldova

Poster: ABCL-013

**Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study**

Anouk Goudsmir<sup>\*</sup>, Edouard Cubilier, Anne-Pascale Meert, Philippe Aftimos, Konstantinos Stathopoulos, Chloé Spilleboudt, Angela Loizidou  
Jules Bordet Institute, Brussels, Belgium

Poster: ABCL-274

**Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry**

Olga Gavrilina<sup>1\*</sup>, Kristina Zakurdaeva<sup>2</sup>, Anastasia Vasileva<sup>1</sup>, Vladimir Vorobyev<sup>3</sup>, Lev Butaev<sup>3</sup>, Vitaly Dubov<sup>1</sup>, Sergey Dubov<sup>4</sup>, Inessa Toropova<sup>5</sup>, Lubov Gavrilova<sup>6</sup>, Marina Popova<sup>7</sup>, Aleksandr Siniaev<sup>7</sup>, Kamil Kaplanov<sup>3</sup>, Andrei Petrenko<sup>3</sup>, Oksana Ochirova<sup>8</sup>, Yulia Sveshnikova<sup>9</sup>, Vasily Shuvaev<sup>10</sup>, Maria Grishunina<sup>11</sup>, Mikhail Kunst<sup>12</sup>, Yulia Chabaeva<sup>1</sup>, Lyubov Al-Radi<sup>1</sup>, Daria Baryshnikova<sup>13</sup>, Elena Gilyazitdinova<sup>1</sup>, Hunan Julhakyan<sup>1</sup>, Valery Savchenko<sup>1</sup>

<sup>1</sup>National Research Center for Hematology, Russia, <sup>2</sup>RakFond, Russia, <sup>3</sup>S.P. Botkin City Clinical Hospital, Moscow, Russia, <sup>4</sup>Regional Clinical Hospital #2(Vladivostok), Russia, <sup>5</sup>Regional Clinical Hospital (Yaroslavl), Russia, <sup>6</sup>Republican Clinical Hospital #4(Saransk), Russia, <sup>7</sup>RM Gorbacheva Research Institute, Pavlov University, Russia, <sup>8</sup>N.A. Semashko Republican Clinical Hospital (Ulan-Ude), Russia, <sup>9</sup>Regional Clinical Hospital (Ekaterinburg), Russia, <sup>10</sup>City Clinical Hospital n.a. V.V. Veresaev Moscow Department of Healthcare, Russia, <sup>11</sup>N.A. Semashko Regional Clinical Hospital (Nizhny Novgorod), <sup>12</sup>Republican Clinical Hospital of Tatarstan, Russia, <sup>13</sup>BUZOO "OKB", Omsk, Russia

Poster: ABCL-334

**Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study**

Annuja Anandaradje<sup>1\*</sup>, Luxitaa Goenka<sup>2</sup>, Biswajit Dubashi<sup>2</sup>, Smita Kayal<sup>2</sup>, Dhanapati Halanaik<sup>3</sup>, Debdatta Basu<sup>4</sup>, Prasanth Ganesan<sup>2</sup>

<sup>1</sup>Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India, <sup>2</sup>Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India, <sup>3</sup>Department of Nuclear medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India, <sup>4</sup>Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India

Poster: ABCL-441

**Demographic and Quality of Life Model Applications to High-Grade Non-Hodgkin Lymphoma Patients in the COVID-19 Era**

Ayman Youssef<sup>1\*</sup>, Dalia Nafea<sup>1</sup>, Nahla Hamed<sup>1</sup>, Israa Okap<sup>3</sup>, Amany Abdelbary<sup>3</sup>, Nermeen Affi<sup>2</sup>, Mostafa Hewalla<sup>2</sup>, Marha Menaisy<sup>2</sup>, Ghada Mohamed<sup>2</sup>, Farida Shaat<sup>2</sup>

<sup>1</sup>Hematology and BMT Unit, Internal Medicine Department, Alexandria, Egypt, <sup>2</sup>Alexandria University Hospitals, Alexandria, Egypt, <sup>3</sup>Pathology Department, Alexandria Faculty of Medicine, Alexandria, Egypt